6-Azacytidine, also known as azacitidine, is a nucleoside analog that acts as a hypomethylating agent. It is a synthetic derivative of cytidine, a naturally occurring nucleoside. 6-Azacytidine is incorporated into DNA and RNA during replication and transcription, leading to inhibition of DNA methylation. This inhibition of DNA methylation can reactivate silenced genes, including tumor suppressor genes, which are often silenced by hypermethylation in cancer cells. 6-Azacytidine has been shown to have significant anti-tumor activity in various hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is also being investigated for its potential therapeutic effects in solid tumors. The importance of 6-azacytidine lies in its ability to target epigenetic modifications, specifically DNA methylation, which plays a crucial role in the development and progression of cancer. Its ability to reactivate silenced genes offers a promising therapeutic strategy for treating cancers with aberrant methylation patterns. The study of 6-azacytidine is driven by its potential to overcome the limitations of traditional chemotherapy and provide a more targeted and effective treatment option for cancer patients.'
6-azacytidine: MH AZACITIDINE refers to 5-azacytidine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65114 |
| CHEMBL ID | 1334069 |
| SCHEMBL ID | 26560 |
| MeSH ID | M0121492 |
| Synonym |
|---|
| 5-amino-2-beta-d-ribofuranosyl-1,2,4-triazin-3(2h)-one |
| ccris 6742 |
| 1,2,4-triazin-3(2h)-one, 5-amino-2-beta-d-ribofuranosyl- |
| as-triazin-3(2h)-one, 4,5-dihydro-5-imino-2-beta-d-ribofuranosyl- |
| nsc 524767 |
| 6-azacytidine (van) |
| as-triazin-3(2h)-one, 5-amino-2-beta-d-ribofuranosyl- |
| as-triazin-3(2h)-one, 5-amino-2beta-d-ribofuranosyl- |
| 1,2,4-triazin-3(2h)-one, 5-amino-2beta-d-ribofuranosyl |
| 5-amino-2-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-2h-[1,2,4]triazin-3-one |
| 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazin-3-one |
| 3131-60-0 |
| 6-azacytidine |
| NCGC00090678-01 |
| 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one |
| NCGC00090678-02 |
| NCGC00258783-01 |
| cas-3131-60-0 |
| dtxsid4020117 , |
| dtxcid40117 |
| tox21_201231 |
| unii-yd42ueh51c |
| yd42ueh51c , |
| 5-amino-1,2,4-triazin-3-one 2-.beta.-d-ribofuranoside |
| 1,2,4-triazin-3(2h)-one, 5-amino-2-.beta.-d-ribofuranosyl- |
| SCHEMBL26560 |
| CHEMBL1334069 |
| 6-chloro-[3,4]-bipyridine |
| Q27294469 |
| 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,3-dihydro-1,2,4-triazin-3-one |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both dosages of 5-azacytidine resulted in significant increases in preimplantation loss, and the high dosage of 5-azacytidine caused a decrease in fertility." | ( Developmental exposure of male germ cells to 5-azacytidine results in abnormal preimplantation development in rats. Doerksen, T; Trasler, JM, 1996) | 0.29 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 14.4233 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| AR protein | Homo sapiens (human) | Potency | 39.9699 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 27.3338 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 21.7120 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 19.3508 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.2189 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 13.8971 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 43.4121 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.7052 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 48.8976 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743094 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 68.6594 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 22.3872 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 1.6335 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 5.3080 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (50.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||